Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pharmesis International's Enterprise Value is S$5.55 Mil.
Pharmesis International's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was S$-0.60 Mil. Therefore, Pharmesis International's EV-to-EBIT ratio for today is -9.22.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Pharmesis International (SGX:BFK) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Pharmesis International's current Enterprise Value is S$5.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Pharmesis International's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was S$-0.60 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Pharmesis International's EV-to-EBITDA for today is:
Pharmesis International's current Enterprise Value is S$5.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Pharmesis International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was S$-0.08 Mil.
Pharmesis International's current Enterprise Value is S$5.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Pharmesis International's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was S$7.89 Mil.
Pharmesis International's current Enterprise Value is S$5.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Pharmesis International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was S$0.36 Mil.
Pharmesis International's current Enterprise Value is S$5.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Pharmesis International's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was S$0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmesis International Enterprise Value Related Terms
Pharmesis International Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:BFK vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmesis International Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Pharmesis International's Enterprise Value falls into.
Pharmesis International Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Pharmesis International's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmesis International (SGX:BFK) has a Enterprise Value of S$5.55 Mil as of Aug. 08, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Pharmesis International and its competitors.
Is Pharmesis International's Enterprise Value too high?
Pharmesis International's current Enterprise Value is S$5.55 Mil. Overall, Pharmesis International has a GF Score™ of 31/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Enterprise Value compare to ZTS and UTHR?
Pharmesis International's Enterprise Value of S$5.55 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Pharmesis International and its competitors. Pharmesis International's current Enterprise Value is S$5.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.09, compared to a current price of S$0.11 — trading 18.9% above its estimated fair value. The current Enterprise Value is S$5.55 Mil. Pharmesis International's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Enterprise Value is S$5.55 Mil as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmesis International (SGX:BFK) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued.
The current stock price of S$0.11 is trading 18.9% above its estimated GF Value™ of S$0.09.
GuruFocus considers Pharmesis International to be Modestly Overvalued.
Key valuation signals for SGX:BFK:
Enterprise Value: S$5.55 Mil
GF Value™: S$0.09 vs. price of S$0.11 (18.9% above fair value)
No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
31GF Score
Get the complete analysis for SGX:BFK
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:BFK has been successfully added to your 
